NA
TTNP

NewEdge Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

NewEdge Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$6 – 3940
2024
Q2 		$6 Hold
1
– – ﹤0.01% 3767
2024
Q1 		$7 Buy
+1
New +$7 ﹤0.01% 3786
2023
Q4 		– Hold
0
– – – 3737

Other funds holding TTNP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

NewEdge Advisors's TTNP Position: Q3 2024 in Review

NewEdge Advisors sold out of Titan Pharmaceuticals (TTNP) in Q3 2024, closing a stake of 1 share — an estimated $6 sold.

NewEdge Advisors first reported a position in TTNP in Q1 2024 and held it in 2 quarters. The position peaked at $7 in Q1 2024. 16 funds tracked by Wall St. Rank hold TTNP as of Q3 2024.

  • NewEdge Advisors reported no remaining Titan Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • NewEdge Advisors sold 1 Titan Pharmaceuticals share in Q3 2024, an estimated $6.
  • NewEdge Advisors first reported a position in Titan Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • NewEdge Advisors's Titan Pharmaceuticals position peaked at $7 in Q1 2024.
  • 16 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.